润都股份(002923.SZ)：目前有1类创新药(化学药)盐酸去甲乌药碱注射液 药品能否获批上市等存在不确定性

Core Viewpoint - The company, Rundu Co., Ltd. (002923.SZ), announced that it is currently developing a Class 1 innovative drug, the hydrochloride injection of nor-ephedrine, and its raw materials, with the drug review process proceeding in an orderly manner [1] Group 1: Drug Development - The innovative drug has a long research and development cycle, significant investment, and high risk characteristics [1] - There is uncertainty regarding whether the drug will be approved for market launch, the timing of such approval, and the subsequent production and sales situation [1] - The short-term impact on the company's performance is expected to be minimal [1]